VERU INC.

VERU is the ticker symbol for VERU INC., a publicly traded US company.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Key metrics include a return on equity of -7.9%, a debt-to-equity ratio of 0.24.

The company reports trailing twelve-month revenue of $4.14M and net loss of $2.74M.

FINOTAUR aggregates real-time and fundamental data on VERU to help traders and investors make informed decisions. Track VERU in your trading journal alongside other positions for a unified view of your portfolio.